Skip to main navigation
Syndax Pharmaceuticals, Inc. logo
  • About Us
    • About Us
    • Leadership
    • Board of Directors
    • Patient Community
  • Focus Areas
    • Focus Areas
    • KMT2Ar Acute Leukemias
    • NPM1m Acute Myeloid Leukemia
    • Chronic Graft-Versus-Host Disease
  • Pipeline
    • Pipeline
    • Menin Inhibitor
    • Anti-CSF-1R Monoclonal Antibody
    • Entinostat
    • Publications & Meeting Presentations
  • Our Products
  • Patients
    • Patients
    • Managed Access Programs
  • Investors
  • Careers
  • News
  • Contact Us

SEC Filing Details

Investors
  • Home
  • Press Releases
  • Events & Presentations
  • Corporate Governance
    • Governance Overview
    • Management
    • Board of Directors
    • Committee Composition
    • Contact the Board
  • Financial Information
    • Financial Overview
    • SEC Filings
    • Annual Reports and Proxies
    • Quarterly Results
    • Key Ratios
  • Stock Information
    • Stock Quote & Chart
    • Historic Stock Lookup
    • Analyst Coverage
    • Analyst Consensus
  • Shareholder Services
    • Investor FAQs
    • Contact Us
    • RSS Feeds
    • Email Alerts

Document Details

Form
10-Q
Filing Date
Nov 3, 2025
Document Date
Sep 30, 2025
Form Description
Quarterly report which provides a continuing view of a company's financial position
Filing Group
Quarterly Filings
Company
Syndax Pharmaceuticals, Inc.
Issuer
Syndax Pharmaceuticals Inc

Filing Formats

iXBRL
View HTML
Download PDF
Download DOC
Download XLS

XBRL

XBRL Viewer
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
XML - XBRL INSTANCE DOCUMENT
Syndax Pharmaceuticals, Inc. logo
  • About Us
  • Focus Areas
  • Pipeline
  • Our Products
  • Patients
  • Investors
  • Careers
  • News
  • Contact Us
Privacy Notice
Cookie Notice
Consumer Health Data Supplemental Privacy Notice
State Regulations
Terms of Use
Limit the Use of My Personal Information
© 2026 Syndax Pharmaceuticals, Inc.
linkedin x.com glassdoor